In the mammalian ventricular myocardium, cholinergic stimulation via vagus nerve or by acetylcholine (ACh) affected the contractile force less than that of atrial muscle (1-4).
In the mammalian ventricular myocardium, cholinergic stimulation via vagus nerve or by acetylcholine (ACh) affected the contractile force less than that of atrial muscle (1) (2) (3) (4) .
Hollenberg and coworkers (5) found first that ACh infused into a coronary artery in dogs caused only a slight negative inotropic action, but that ACh infused in the same concen tration during sympathetic stimulation or during noradrenaline infusion induced a profound myocardial depression. These observations were confirmed in the dog (6-8), rabbit and turtle (9) , and cat (10) hearts.
The subcellular mechanisms underlying these adrenergic-cholinergic interactions were elucidated by the observations that cyclic AMP and cyclic GMP exerted the opposing regulatory action on the myocardial contraction (11) (12) (13) (14) . It was shown that the PIA of ,3-adrenoceptor stimulation was accompanied by an increase in cyclic AMP levels and by a concomitant decrease in cyclic GMP levels in the isolated perfused rat heart (15); ACh induced negative isotropic effect was associated with an elevation of cyclic GMP levels and with the opposite change in cyclic AI\IP levels iii the same preparation (10, 17) . Based on these and their own findings in the guinea-pig heart (18) , it has been proposed that the anti-adrenergic effects of cholinergic stimulation in the mammalian ventricular muscle may be mediated by the specific antagonism of the intracellular actions of cyclic AMP by cyclic GMP.
Besides ,3-adrenoceptor stimulants which stimulate adenylate cyclase , histamine (19) (20) (21) and glucagon (22, 23) , as well as cyclic AMP phosphodiesterase (PDE) inhibitors, theophyl line (24) and papaverine (25, 26) All experiments for chemical assay were carried out in the paired muscle isolated from the same heart in the presence of agonists alone and agonists plus carbachol. Three minutes after the administration of carbachol in the presence of each agonist, muscles were removed from the organ bath, frozen immediately in liquid nitrogen and homogenized in 0.5 ml of 5 % trichloroacetic acid, as described in detail in the previous paper (27) . After homogeni zation, 100 ,' l portions of the supernatant were extracted five times with I ml of ether after adding I N HCI. The cyclic AMP and cyclic GMP contents were determined by the radio immunoassay methods after succinylation of the nucleotides (28) (29) (30) (31) the anti-cyclic AMP and -cyclic GMP sera and ('23I)-succinyl cyclic AMP and cyclic GMP tyrosine methyl ester (Yamasa Shoyu Co., Choshi). The solution of isoprenaline was prepared in 1 % ascorbic acid on each experimental day and diluted with 0.9 % saline solution.
Glucagon and histamine were dissolved in saline on each experimental day. These solutions were kept ice-cooled during experiments. In contrast to the prominent inhibitory action of carbachol on response to the agents shown above, carbachol (10 ,N) failed to inhibit positive inotropic actions of calcium or g-strophanthin (Fig. 2) , the actions of which occurred with no change in the intracellular cyclic AMP level (24, 32 The summarized data of these experiments are presented in Fig. 3 . Changes in the tension developed caused by carbachol (10 ; tM) under myocardial stimulation produced by isoprenaline, glucagon, histamine, papaverine, theophylline or dbcAMP were highly sig nificant (P<0.001 for each agonist).
Actions of calcium and g-strophanthin were not significantly affected by carbachol.
Influence of carbachol on cyclic AMP and cyclic GMP levels during clrolinergic antagonism of positive inotropic actions: Intracellular cyclic AMP and cyclic GMP levels were deter mined when positive inotropic actions were caused by isoprenaline, histamine, glucagon, papaverine or theophylline, and when these actions were inhibited by 3 ,tM carbachol.
Results are suntnlari,ed in 'Fable 1. Cyclic AMI' levels were increased significantly by each agonist from control levels of 0.80---0.95 pmol/ing w.w. at the time of determination described in Table 1 . Carbachol (3 /N) administered to one of the paired muscle 3 rnin before the determination decreased significantly (P values are presented in Table IA) actions, which were inhibited by cholinergic stimulation, were accompanied by a simultaneous elevation of the cyclic AMP level (15-27, 32-34, 37) , while those, which were not inhibited,
were not accompanied by elevations in the cyclic AMP levels (18, 24, 32) , it appears that the cholinergic antagonism in the mammalian ventricular myocardium is indeed specific to actions related to an elevation of cyclic AMP levels, as previously suggested by Watanabe and Besch (18) . Our recent observations that the positive inotropic action mediated via a-adrenoceptors in the rabbit papillary muscle was not inhibited by the same concentration of carbachol (35) support this hypothesis.
Gardner and Allen (33) have shown that in the perfused rat heart ACh reduced cyclic AMP levels and phosphorylase activity when the levels and activity were elevated above basal values by adrenaline.
In the same preparation, Keely and coworkers (34) demon strated that ACh antagonized the adrenaline-produced increases in cyclic AMP levels and in contractile force, and activations of cyclic AMP-dependent protein kinase and of phos phorylase. These changes were accompanied by increased cyclic GMP levels (33, 34) .
Consistent with these findings in the rat heart, carbachol, another cholinergic agent, reduced the elevation of cyclic AMP levels by isoprenaline, during the inhibition of the positive inotropic action of isoprenaline in the dog ventricular muscle. Furthermore, the elevation of cyclic AMP levels produced by histamine, glucagon, theophylline or papaverine was also abolished during the carbachol-induced inhibition of the positive inotropic actions of these agents. The findings that there was a good correlation between levels of cyclic AMP and changes in developed tension during cholinergic antagonism, and that the relationship between cyclic AMP levels and contractile force was not changed during cholinergic an tagonism suggest that the reduction of cyclic AMP levels is involved in the antagonism caused by carbachol.
In adenylate cyclase preparations isolated from dog (36) and cat (37) inhibitors, theophylline and papaverine was abolished by carbachol in the present experi ments.
In the PDE preparation of rabbit hearts LaRaia and Sonnenblick (37) found no significant difference between the normal activity and that with 10 1tM carbachol.
Thus, it appears unlikely that carbachol stimulates directly the PDE activity. Alternatively, it is noteworthy that PDE preparations from a number of sources, including rat liver (38) , rat adipose tissue 
